Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges

K. Parikh, L.E.L. Hendriks, P. Bironzo, J. Remon*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Article number102250
Number of pages8
JournalCancer Treatment Reviews
Volume99
DOIs
Publication statusPublished - 1 Sep 2021

Keywords

  • Mesothelioma
  • Immune checkpoint inhibitors
  • Nivolumab
  • Pembrolizumab
  • Ipilimumab
  • MALIGNANT PLEURAL MESOTHELIOMA
  • PHASE-II TRIAL
  • OPEN-LABEL
  • SINGLE-ARM
  • PLUS IPILIMUMAB
  • T-CELLS
  • CHEMOTHERAPY
  • MULTICENTER
  • NIVOLUMAB
  • SAFETY

Cite this